Inhibitors of Phosphoinositol 3 Kinase and NFκB for the Treatment of Chronic Obstructive Pulmonary Disease

Author(s): Nancy E. Larocca, Dolores Moreno, Jenny V. Garmendia, Juan B. De Sanctis.

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 5 , Issue 3 , 2011

Become EABM
Become Reviewer

Abstract:

Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized mainly by pulmonary airflow limitation that is not fully reversible. New different pharmacological approaches to decrease inflammation of the airways and consequently disease progression and increase airway obstruction reversibility have been developed. In the present article, we review the new patents on phosphoinositide 3 kinase and NFκb inhibitors for future therapies.

Keywords: Alkylamines, azol-pyrimidines derivatives, chronic obstructive pulmonary disease, imidazolines, mTOR inhibitors, NFkb inhibitors, Phosphoinositide 3 kinase, quinazolines, triazoles, spirometry test, lipid kinases, oncogenes

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 5
ISSUE: 3
Year: 2011
Page: [178 - 183]
Pages: 6
DOI: 10.2174/187221311797264928

Article Metrics

PDF: 18